[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroenteritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroenteritis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,88,111,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100614914","phase-4-rifaximin-200-mg-plus-oral-rehydration-vs-oral-rehydration-alone-in-children-with-acute-diarrhea-100614914",false,"NCT07285785","Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","A Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone","Inclusion Criteria:\n\n1. Consent and assent are appropriately obtained prior to any study related activities, including discontinuation of any prohibited medications (subjects must sign an assent for the study and a parent or a legal guardian must sign the informed consent).\n2. Subject is between 6 to 11 (and 11 months) years of age, inclusive, and weighs at least 15 kg (33 lbs) at Screening.\n3. Females of childbearing (reproductive) potential must have a negative urine and serum pregnancy test at Screening and agree to use a highly effective method of contraception throughout their participation in the study. Acceptable methods of contraception are those alone or in combination, that result in a low failure rate (ie, less than 1% per year) when used consistently and correctly and include hormonal methods (oral, injected or implanted), intrauterine device or intrauterine system or double barrier methods (simultaneous use of a physical barrier method by the subject and male partner, including a male condom and an occlusive cap \\[diaphragm or cervical\u002Fvault cap\\] with spermicidal). Abstinence or partner(s) with a vasectomy may be considered an acceptable method of contraception at the discretion of the Investigator.\n\n   NOTE: Female subjects are considered of child-bearing potential if they are (a) physiologically capable of becoming pregnant, defined as a female who has experienced menarche and (b) they will be, or could possibly be, engaging in sexual activity during the course of the study.\n4. Subject has diarrhea of suspected bacterial etiology defined by:\n\n   * At least 3 unformed stools in the last 24 hours prior to Screening.\n   * A fever ≥ 100.4°F (38°C) and ≤ 102.2°F (39°C) or has had a fever of ≥ 100.4°F (38°C) and ≤ 102.2°F (39°C) at any time since the development of abdominal pain or diarrhea.\n   * Illness for less than 96 hours at Screening.\n5. Parent or legal guardian and subject, when applicable based on aged, are capable of understanding the requirements of the study and willing to comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Subject has a history of chronic diarrhea.\n2. Subject is unable to eat or drink.\n3. Subject has at least one of the following signs or symptoms:\n\n   * Presence of fever \\>39°C (\\>102.2°F).\n   * Presence of frank blood in stool.\n4. Subject has taken \\>2 doses of anti-diarrheal therapies in the 24 hours prior to randomization.\n5. Subject has taken any oral antimicrobial drug within 14 days of randomization.\n6. Subject has an unstable medical condition, in the opinion of the Investigator, (including, but not limited to, evidence of severe dehydration noted by tachycardia, abnormal blood pressure, or decreased skin turgor) at the Screening visit.\n7. Subject has known, clinically significant hepatic disease manifested by twice the age and sex-adjusted upper limit of normal (2 × ULN) for any of the following liver function tests: alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, or total bilirubin (except in isolated elevation of unconjugated bilirubin).\n8. Subject has known, clinically significant renal disease (eg, 1.5 × ULN of serum creatinine or 2 × ULN of blood urea nitrogen levels).\n9. Subject has serum sodium of ≥150 mEq\u002FL and serum potassium ≤3.0 mEq\u002FL.\n10. Subject has a known hypersensitivity or allergy to Xifaxan®, rifampin, rifamycin-derived antibiotics, or any of the components of the rifaximin (Xifaxan®) formulations used in this study.\n11. Subject is pregnant or lactating or plans to become pregnant during the study.\n12. Subject has had a previous history of malignancy.\n13. Subject has a history of tuberculosis infection and\u002For has received treatment for tuberculosis infection.\n14. Subject has any concurrent illness, disability or circumstance that may affect the interpretation of clinical data, could cause noncompliance with treatment or visits or otherwise contraindicates participation in this study in the opinion of the Investigator.\n15. Subject has had significant blood loss within the 30 days prior to the Screening visit which prevents the collection of the blood volume required for this study.\n16. Subject has participated in an investigational drug or device study within the 30 days prior to randomization.\n17. Subject's parent or legal guardian, or an immediate family member is an employee of the site that is directly involved in the management, administration, or support of this study.\n18. Subject and\u002For legal guardian is unwilling or unable to comply with the study protocol for any other reason.\n19. Subject has a serum glucose level at screening that deviates from the reference range established by the central laboratory.\n20. Subject is taking a concomitant medication that is a P-glycoprotein (P-gp) inhibitor.\n21. Subject is taking warfarin for a pre-existing condition.","ALL","6 Years","12 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are:\n\nHow does rifaximin 200 mg move through and leave the body in children with acute diarrhea?\n\nIs rifaximin safe for children in this age group?\n\nDoes rifaximin plus ORT help resolve diarrhea faster than ORT alone?\n\nResearchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes.\n\nParticipants will:\n\nTake one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone\n\nReceive oral rehydration therapy according to the investigator's standard of care\n\nAttend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls\n\nProvide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only)\n\nProvide stool samples to identify bacterial pathogens\n\nKeep a diary of stool frequency and consistency to help determine when diarrhea resolves\n\nBe monitored for side effects, vital signs, and laboratory changes",[27,28,29],"Diarrhea","Gastroenteritis","Bacterial Infection",[31,32,33,34,35,36,37,38,39,40,41],"pediatric","children","rifaximin","xifaxan","Oral Rehydration Therapy (ORT)","acute diarrhea","bacterial diarrhea","gastroenteritis","open-label","randomized","ages 6-11","RECRUITING","2026-03-17",{"date":45,"type":46},"2026-03-18","ACTUAL",{"date":48,"type":46},"2026-02-11",{"date":50,"type":21},"2027-07-31",{"name":52,"class":53},"Bausch Health Americas, Inc.","INDUSTRY",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100475513","follow-up-automatically-vs-as-needed-comparison-faan-c-trial-100475513","NCT05471908","Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial","The Follow-up Automatically vs. As-Needed Comparison Trial","FAAN-C","Inclusion Criteria:\n\n* Age \\\u003C18 years at the time of randomization\n* Hospitalization due to a primary diagnosis of pneumonia, skin and soft tissue infection, acute gastroenteritis, or urinary tract infection.\n* Parent speaks English or Spanish.\n\nExclusion Criteria:\n\n* Presence of a comorbid disease that is both chronic and complex\n* Principal disease required surgical intervention (beyond superficial incision and drainage)\n* Immunodeficiency\n* A well-child check-up or post-hospitalization follow-up visit is already scheduled within 7 days of hospital discharge\n* Parent or participant strongly prefers PRN or automatic follow-up\n* A medical provider feels strongly that a post-hospitalization follow-up visit is needed within 7 days of hospital discharge\n* Sibling concurrently hospitalized\n* Unable to identify a clinic where the participant would receive any needed post-hospitalization follow-up\n* Diagnosis of pneumonia complicated by:\n\n  o Receiving a chest tube\n* Diagnosis of urinary tract infection complicated by:\n\n  * History of neurogenic bladder or urologic surgery\n  * Renal imaging anticipated within 7 days of hospital discharge\n  * Renal abscess\n* Diagnosis of skin and soft tissue infection complicated by:\n\n  * Chronic wound\n  * Postoperative infection\n  * Predisposition to poor wound healing\n  * Discharging with a drain in place\n  * Complicated by necrotizing fasciitis or toxic shock syndrome\n* Diagnosis of gastroenteritis complicated by:\n\n  * Hemolytic uremic syndrome","18 Years",{"count":64,"type":21},2674,[66],"NA","Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.",[69,70,71,28],"Pneumonia","Urinary Tract Infections","Soft Tissue Infections",[73,74,75,76],"post-hospitalization","follow-up care","patient centered care","randomized control trial","2025-12-03",{"date":79,"type":46},"2025-12-10",{"date":81,"type":46},"2022-08-22",{"date":83,"type":21},"2028-02-28",{"name":85,"class":86},"University of Utah","OTHER",14,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":4},"100506607","phase-3-clinical-trial-to-investigate-the-efficacy-and-safety-of-ondansetron-danset---adwia-versus-placebo-plus-the-standard-of-care-in-the-treatment-of-nausea-and-vomiting-in-adult-patients-with-acute-gastroenteritis-100506607","NCT05876585","Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis","A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis","Inclusion Criteria:\n\n1. Male or female patients aged between 18 and 65 years.\n2. Patients diagnosed with acute gastroenteritis visiting the emergency room.\n3. Patients considered by the attending physician to need an anti-emetic medication.\n4. Patients able and willing to provide written informed consent.\n5. Patients able and willing to complete the study procedures including compliance with the requirements and restrictions listed in the consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Patients who received an anti-emetic medication during the past 24 hours.\n3. History of hypersensitivity to any components of ondansetron or metoclopramide injection.\n4. History of hypersensitivity to other selective 5HT3 receptor antagonists.\n5. Patients with moderate or severe impairment of hepatic function.\n6. Patients with moderate or severe renal impairment.\n7. Patients with congenital long QT syndrome.\n8. Patients who have or may develop prolongation of Qtc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmia, or patients taking other medicinal products that lead to QT prolongation or electrolyte imbalance.\n9. Patients with hypokalemia or hypomagnesemia.\n10. Patients with signs of subacute intestinal obstruction.\n11. Patients currently using apomorphine hydrochloride.\n12. Patients currently using levodopa or dopamine agonists.\n13. Patients with gastrointestinal hemorrhage, mechanical obstruction, or gastrointestinal perforation.\n14. Patients with a known history of neuroleptic- or metoclopramide-induced tardive dyskinesia.\n15. Patients with epilepsy.\n16. Patients with Parkinson's disease.\n17. Patients with confirmed or suspected pheochromocytoma.\n18. Patients with a known history of methemoglobinemia with metoclopramide or NADH-cytochrome b5 reductase deficiency.\n19. Patients with a history of clinically-significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol.\n20. Patients with any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial.\n21. Receipt of an investigational drug within 6 months prior to screening, or active enrolment in another investigational medication or device trial.\n22. Inability to understand and cooperate with the investigators or to give valid consent.","65 Years",{"count":97,"type":21},126,[99],"PHASE3","A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.",[28],"NOT_YET_RECRUITING","2024-09-24",{"date":105,"type":46},"2024-09-26",{"date":107,"type":21},"2025-06-01",{"date":107,"type":21},{"name":110,"class":53},"Genuine Research Center, Egypt",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":119,"enrollmentInfo":120,"targetDuration":122,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100556414","prevalence-of-faecal-bacteriophage-in-patients-with-digestive-symptoms-100556414","NCT06524791","Prevalence of Faecal Bacteriophage in Patients With Digestive Symptoms","Evaluation of the Prevalence of Faecal Bacteriophage Carriage in Patients With Digestive Symptoms.","PREPHAGE","Inclusion Criteria:\n\n* Age between 18 and 60.\n* Persons having developed gastrointestinal symptoms justifying microbiological stool testing at the time of hospitalization.\n* Person having received full information on the organization of the research and not having objected to the use of this data\n\nExclusion Criteria:\n\n* Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code.\n* Pregnant or breast-feeding women,\n* Minors (not emancipated),\n* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice),\n* Persons of full age who are unable to give their consent.\n* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1.","60 Years",{"count":121,"type":21},300,"1 Day","OBSERVATIONAL","Define the prevalence of fecal phage carriage in individuals with digestive symptoms (i) Determine the concentrations of infectious fecal phages in the stools of individuals with digestive symptoms (detection by culture)\n\n(ii) Determine fecal phage genome concentrations in the stools of individuals with digestive symptoms (PCR detection)\n\n(iii) Explore factors that could impact fecal phage carriage (patients with digestive symptoms vs. healthy individuals, immunocompromised patients vs. immunocompetent patients)",[28],[127],"bacteriophages","2024-07-27",{"date":130,"type":46},"2024-07-30",{"date":132,"type":21},"2024-11-15",{"date":134,"type":21},"2025-11-15",{"name":136,"class":86},"Central Hospital, Nancy, France",1,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":146,"enrollmentInfo":147,"targetDuration":149,"studyType":123,"phases":4,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":137},"100398696","pediatric-and-ambulatory-research-in-infectious-diseases-100398696","NCT04471493","Pediatric and Ambulatory Research in Infectious Diseases","Real Time Surveillance of Pediatric Infectious Diseases in French Ambulatory Care: PARI Study","PARI","Inclusion Criteria:\n\n* Children under 16 years of age with at least one infectious disease among:\n* pharyngitis\n* otitis\n* pneumonia\n* influenza\n* bronchiolitisz\n* varicella\n* gastroenteritis\n* enterovirus disease\n* bordetella pertussis disease\n* using the same same software, Axi5-Infansoft (developed by CompuGroup Medical, Nanterre, France)\n\nExclusion Criteria:\n\n* parental refusal","16 Years",{"count":148,"type":21},400000,"5 Years","Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network. Here we aim to set up a surveillance network on pediatric infectious diseases with an investment in teaching with specific trainings of participating pediatricians, increasing in use of point of care tests, and automated data extraction from the computers of the pediatricians.",[152,153,154,155,156,69,28],"Otitis","Bronchiolitis","Influenza","Pharyngitis","Varicella",[158,159,160,161,162],"Vaccination","Antibiotic treatment","Point of care test","automated data extraction","network","2024-02-07",{"date":165,"type":46},"2024-02-08",{"date":167,"type":46},"2017-06-26",{"date":169,"type":21},"2030-08-02",{"name":171,"class":86},"Association Clinique Thérapeutique Infantile du val de Marne"]